MoonLake Stockholders with Large Losses are Encouraged to Contact Robbins LLP for Information About the Class Action Against MLTX
MoonLake Immunotherapeutics(US:MLTX) Globenewswire·2025-10-28 05:24SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Company: MoonLake is a Swiss clinical-stage biotechnology company focused on inflammatory diseases driven by interleukin-17 (IL-17), particularly in dermatology and rheumatology. Class Period: March 10, 2024 - September 29, 2025 The Case: Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired MoonLake Immunotherapeutics common stock because the Company allegedly misled investors regarding the ...